Dr Louise Kostos
Clinical (Lecturer)
The Sir Peter MacCallum Department of Oncology
25 Scholarly works
0 Projects
HIGHLIGHTS
2025
Journal article
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
DOI: 10.2967/jnumed.125.2708042025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Journal article
Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer
DOI: 10.1111/bju.167512025
Journal article
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
DOI: 10.1016/S1470-2045(25)00332-82025
Journal article
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
DOI: 10.2967/jnumed.124.2686402025
Journal article
Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
DOI: 10.2967/jnumed.124.2692522025
Journal article
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer
DOI: 10.1016/j.eururo.2025.01.010
RECENT SCHOLARLY WORKS
2025
Journal article
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
DOI: 10.1016/j.eururo.2025.08.0152024
Journal article
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
DOI: 10.1016/S1470-2045(24)00440-62024
Journal article
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
DOI: 10.1007/s40265-024-02071-y